Background: Acetylshikonin, a major constituent isolated from Arnebia euchroma, is a potential candidate for anti-colorectal cancer drugs. However, the potential activity and underlying mechanism of A cetylshikonin against colorectal cancer remain unclear. Methods: In this study, Acetylshikonin was isolated from the active CHCl3 extract of Arnebia euchroma using activity-guided screening, and elucidated by the extensive spectroscopic analysis and comparison with literature data. Human colorectal cancer cells HT29, DLD-1, HCT116 or Caco-2 were exposed to different concentrations of Acetylshikonin (6.25 - 100 μg/mL) for 24 or 48 h. Cell viability, cell apoptosis and cell cycle distribution were detected . The activity of Acetylshikonin and potential mechanism of the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway were evaluated in vitro and vivo . Results: We found that Acetylshikonin exhibited remarkable anti-proliferative activity in a dose-dependent manner against HT29 cells with the IC50 values of 60.82 μg/ml and 30.78 μg/ml at 24, 48 h, respectively . Moreover, A cetylshikonin induced cell cycle arrest at G0/G1 phase and early apoptosis through inhibition of PI3K/Akt/mTOR pathway. Furthermore, the assays of cell inhibition, early apoptosis and G0/G1 phase distribution showed that suppression of the PI3K/Akt pathway using LY294002 enhanced the anti-cancer effect of Acetylshikonin. Similarly, A cetylshikonin also decreased the growth of tumour in colorectal cancer xenografts in mice through PI3K/Akt/mTOR pathway. Conclusions: To sum up, t hese new findings provided a framework for further exploration of Acetylshikonin which possessed the potential antitumor activity by inhibiting PI3K/Akt/mTOR pathway.
Benard, F., Barkun, A.N., Martel, M. and von Renteln, D. (2018) Systematic Review of Colorectal Cancer Screening Guidelines for Average-Risk Adults: Summarizing the Current Global Recommendations. World Journal of Gastroenterology, 24, 124-138. https://doi.org/10.3748/wjg.v24.i1.124
Miguel, A., Azevedo, L.F., Araujo, M. and Pereira, A.C. (2012) Frequency of Adverse Drug Reactions in Hospitalized Patients: A Systematic Review and Meta-Analysis. Pharmacoepidemiology and Drug Safety, 21, 1139-1154. https://doi.org/10.1002/pds.3309
Liang, W., Cai, A., Chen, G., Xi, H., Wu, X., Cui, J., Zhang, K., Zhao, X., Yu, J., Wei, B. and Chen, L. (2016) Shikonin Induces Mitochondria-Mediated Apoptosis and Enhances Chemotherapeutic Sensitivity of Gastric Cancer through Reactive Oxygen Species. Scientific Reports, 6, Article ID: 38267. https://doi.org/10.1038/srep38267
Li, X., Fan, X.X., Jiang, Z.B., Loo, W.T., Yao, X.J., Leung, E.L., Chow, L.W. and Liu, L. (2017) Shikonin Inhibits Gefitinib-Resistant Non-Small Cell Lung Cancer by Inhibiting TrxR and Activating the EGFR Proteasomal Degradation Pathway. Pharmacological Research, 115, 45-55. https://doi.org/10.1016/j.phrs.2016.11.011
Wang, Y., Zhou, Y., Jia, G., Han, B., Liu, J., Teng, Y., Lv, J., Song, Z., Li, Y., Ji, L., Pan, S., Jiang, H. and Sun, B. (2014) Shikonin Suppresses Tumour Growth and Synergizes with Gemcitabine in a Pancreatic Cancer Xenograft Model: Involvement of NF-κB Signalling Pathway. Biochemical Pharmacology, 88, 322-333. https://doi.org/10.1016/j.bcp.2014.01.041
Tang, S., Chen, A., Zhou, X., Zeng, L., Liu, M. and Wang, X. (2017) Assessment of the Inhibition Risk of Shikonin on Cytochrome P450 via Cocktail Inhibition Assay. Toxicology Letters, 281, 74-83. https://doi.org/10.1016/j.toxlet.2017.09.014
Huang, G., Zhao, H.R., Meng, Q.Q., Zhang, Q.J., Dong, J.Y., Zhu, B.Q. and Li, S.S. (2018) Synthesis and Biological Evaluation of Sulfur-Containing Shikonin Oxime Derivatives as Potential Antineoplastic Agents. European Journal of Medicinal Chemistry, 143, 166-181. https://doi.org/10.1016/j.ejmech.2017.11.031
Ning, X., Qi, H., Li, R., Li, Y., Jin, Y., McNutt, M.A., Liu, J. and Yin, Y. (2017) Discovery of Novel Naphthoquinone Derivatives as Inhibitors of the Tumour Cell Specific M2 Isoform of Pyruvate Kinase. European Journal of Medicinal Chemistry, 138, 343-352. https://doi.org/10.1016/j.ejmech.2017.06.064
Park, S.H., Phuc, N.M., Lee, J., Wu, Z., Kim, J., Kim, H., Kim, N.D., Lee, T., Song, K.S. and Liu, K.H. (2017) Identification of Acetylshikonin as the Novel CYP2J2 Inhibitor with Anti-Cancer Activity in HepG2 Cells. Phytomedicine, 24, 134-140. https://doi.org/10.1016/j.phymed.2016.12.001
Cho, S.C. and Choi, B.Y. (2015) Acetylshikonin Inhibits Human Pancreatic PANC-1 Cancer Cell Proliferation by Suppressing the NF-κB Activity. Biomolecules & Therapeutics, 23, 428-433. https://doi.org/10.4062/biomolther.2015.102
Ko, F.N., Lee, Y.S., Kuo, S.C., Chang, Y.S. and Teng, C.M. (1995) Inhibition on Platelet Activation by Shikonin Derivatives Isolated from Arnebia euchroma. Biochimica et Biophysica Acta (BBA), Molecular Cell Research, 1268, 329-334. https://doi.org/10.1016/0167-4889(95)00078-7
Qi, F., Zhao, L., Zhou, A., Zhang, B., Li, A., Wang, Z. and Han, J. (2015) The Advantages of Using Traditional Chinese Medicine as an Adjunctive Therapy in the Whole Course of Cancer Treatment instead of Only Terminal Stage of Cancer. BioScience Trends, 9, 16-34. https://doi.org/10.5582/bst.2015.01019
Marquez-Jurado, S., Diaz-Colunga, J., Das Neves, R.P., Martinez-Lorente, A., Almazan, F., Guantes, R. and Iborra, F.J. (2018) Mitochondrial Levels Determine Variability in Cell Death by Modulating Apoptotic Gene Expression. Nature Communications, 9, 389. https://doi.org/10.1038/s41467-017-02787-4
Fulda, S. (2018) Cell Death-Based Treatment of Glioblastoma. Cell Death & Disease, 9, 121. https://doi.org/10.1038/s41419-017-0021-8
Zheng, T., Que, Z., Jiao, L., Kang, Y., Gong, Y., Yao, J., Ma, C., Bi, L., Dong, Q., Zhao, X. and Xu, L. (2017) Herbal Formula YYJD Inhibits Tumour Growth by Inducing Cell Cycle Arrest and Senescence in Lung Cancer. Scientific Reports, 7, Article No. 4984. https://doi.org/10.1038/s41598-017-05146-x
Chen, X., Wu, Q.S., Meng, F.C., Tang, Z.H., Chen, X., Lin, L.G., Chen, P., Qiang, W.A., Wang, Y.T., Zhang, Q.W. and Lu, J.J. (2016) Chikusetsusaponin IVa Methyl Ester Induces G1 Cell Cycle Arrest, Triggers Apoptosis and Inhibits Migration and Invasion in Ovarian Cancer Cells. Phytomedicine, 23, 1555-1565. https://doi.org/10.1016/j.phymed.2016.09.002
Chen, D., Lin, X., Zhang, C., Liu, Z., Chen, Z., Li, Z., Wang, J., Li, B., Hu, Y., Dong, B., Shen, L., Ji, J., Gao, J. and Zhang, X. (2018) Dual PI3K/mTOR Inhibitor BEZ235 as a Promising Therapeutic Strategy against Paclitaxel-Resistant Gastric Cancer via Targeting PI3K/Akt/mTOR Pathway. Cell Death & Disease, 9, 123. https://doi.org/10.1038/s41419-017-0132-2
Pan, Y., Wang, N., Xia, P., Wang, E., Guo, Q. and Ye, Z. (2018) Inhibition of Rac1 Ameliorates Neuronal Oxidative Stress Damage via Reducing Bcl-2/Rac1 Complex Formation in Mitochondria through PI3K/Akt/mTOR Pathway. Experimental Neurology, 300, 149-166. https://doi.org/10.1016/j.expneurol.2017.10.030
Wang, F., Wang, Q., Zhou, Z.W., Yu, S.N., Pan, S.T., He, Z.X., Zhang, X., Wang, D., Yang, Y.X., Yang, T., Sun, T., Li, M., Qiu, J.X. and Zhou, S.F. (2015) Plumbagin Induces Cell Cycle Arrest and Autophagy and Suppresses Epithelial to Mesenchymal Transition Involving PI3K/Akt/mTOR-Mediated Pathway in Human Pancreatic Cancer Cells. Drug Design Development and Therapy, 9, 537-560.
Ackermann, M.A., King, B., Lieberman, N.A.P., Bobbili, P.J., Rudloff, M., Berndsen, C.E., Wright, N.T. and Hecker, P.A. (2017) Kontrogianni-Konstantopoulos A. Novel Obscurins Mediate Cardiomyocyte Adhesion and Size via the PI3K/AKT/mTOR Signalling Pathway. Journal of Molecular and Cellular Cardiology, 111, 27-39. https://doi.org/10.1016/j.yjmcc.2017.08.004
Xie, Y., Naizabekov, S., Chen, Z. and Tokay, T. (2016) Power of PTEN/AKT: Molecular Switch between Tumour Suppressors and Oncogenes. Oncology Letters, 12, 375-378. https://doi.org/10.3892/ol.2016.4636
Courtney, K.D., Corcoran, R.B. and Engelman, J.A. (2010) The PI3K Pathway as Drug Target in Human Cancer. Journal of Clinical Oncology, 28, 1075-1083. https://doi.org/10.1200/JCO.2009.25.3641
Tonlaar, N., Galoforo, S., Thibodeau, B.J., Ahmed, S., Wilson, T.G., Yumpo Cardenas, P., Marples, B. and Wilson, G.D. (2017) Antitumour Activity of the Dual PI3K/MTOR Inhibitor, PF-04691502, in Combination with Radiation in Head and Neck Cancer. Radiotherapy and Oncology, 124, 504-512. https://doi.org/10.1016/j.radonc.2017.08.001
Pandurangan, A.K. (1970) Potential Targets for Prevention of Colorectal Cancer: A Focus on PI3K/Akt/mTOR and Wnt Pathways. Asian Pacific Journal of Cancer Prevention, 14, 2201-2205. https://doi.org/10.7314/APJCP.2013.14.4.2201
Liu, Y., Bi, T., Wang, Z., Wu, G., Qian, L., Gao, Q. and Shen, G. (2016) Oxymatrine Synergistically Enhances Antitumour Activity of Oxaliplatin in Colon Carcinoma through PI3K/AKT/mTOR Pathway. Apoptosis, 21, 1398-1407. https://doi.org/10.1007/s10495-016-1297-3